Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Chianese

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cellsCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Journal for Immunotherapy of Cancer|May 10, 2020
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanomaVictor H Engelhard, Rebecca C Obeng, Kara L Cummings, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)Craig L Slingluff, Gina R Petroni, Kerrington R Molhoek, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cellsCraig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Journal for Immunotherapy of Cancer|May 10, 2020
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanomaVictor H Engelhard, Rebecca C Obeng, Kara L Cummings, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2013
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)Craig L Slingluff, Gina R Petroni, Kerrington R Molhoek, et al.
Pageof 6